secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACADIA PHARMACEUTICALS INC (ACAD)
CIK:        0001070494
Form:       8-K
Filed at:   2025-11-05T23:59:59+00:00
Accession:  0001193125-25-266959
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acadia Q3 revenue $278.6M (+11% YoY); net income $71.8M; raises FY 2025 guidance
--------------------------------------------------------------------------------

- Q3 net product sales: NUPLAZID $177.5M (+12% YoY), DAYBUE $101.1M (+11% YoY).
- Q3 net income $71.8M ($0.42 diluted EPS) vs. $32.8M ($0.20) in Q3 2024.
- Full-year 2025 total revenue guidance raised to $1.07-1.095B from $1.045-1.095B.
- NUPLAZID guidance raised to $685-695M; DAYBUE guidance tightened to $385-400M.
- Cash & investments $847M at Sept 30, 2025 vs. $756M at Dec 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1070494/000119312525266959/0001193125-25-266959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1070494/000119312525266959/acad-20251105.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-266959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer